A detailed history of Royal Bank Of Canada transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Royal Bank Of Canada holds 49,724 shares of ATAI stock, worth $70,110. This represents 0.0% of its overall portfolio holdings.

Number of Shares
49,724
Previous 49,724 -0.0%
Holding current value
$70,110
Previous $66,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.27 - $2.6 $2,540 - $5,200
-2,000 Reduced 3.87%
49,724 $66,000
Q1 2024

Nov 05, 2024

BUY
$1.5 - $2.19 $3,000 - $4,380
2,000 Added 4.02%
51,724 $101,000
Q1 2024

May 15, 2024

BUY
$1.5 - $2.19 $2,356 - $3,440
1,571 Added 3.13%
51,724 $101,000
Q4 2023

Feb 14, 2024

SELL
$1.04 - $1.55 $3,395 - $5,060
-3,265 Reduced 6.11%
50,153 $70,000
Q3 2023

Nov 14, 2023

SELL
$1.27 - $2.28 $19 - $34
-15 Reduced 0.03%
53,418 $68,000
Q2 2023

Aug 14, 2023

BUY
$1.44 - $2.19 $1,962 - $2,984
1,363 Added 2.62%
53,433 $91,000
Q1 2023

May 15, 2023

BUY
$1.17 - $2.7 $276 - $637
236 Added 0.46%
52,070 $94,000
Q4 2022

Feb 14, 2023

BUY
$2.38 - $3.55 $3,479 - $5,190
1,462 Added 2.9%
51,834 $137,000
Q3 2022

Nov 14, 2022

SELL
$3.14 - $4.87 $24,652 - $38,234
-7,851 Reduced 13.48%
50,372 $167,000
Q2 2022

Aug 15, 2022

BUY
$3.03 - $5.32 $21,022 - $36,910
6,938 Added 13.53%
58,223 $211,000
Q1 2022

May 16, 2022

BUY
$4.66 - $7.66 $224,775 - $369,480
48,235 Added 1581.48%
51,285 $261,000
Q4 2021

Feb 14, 2022

SELL
$6.82 - $17.8 $7,467 - $19,491
-1,095 Reduced 26.42%
3,050 $23,000
Q3 2021

Nov 15, 2021

BUY
$13.62 - $19.48 $50,394 - $72,076
3,700 Added 831.46%
4,145 $61,000
Q2 2021

Aug 16, 2021

BUY
$16.94 - $19.89 $7,538 - $8,851
445 New
445 $8,000

Others Institutions Holding ATAI

About ATAI Life Sciences N.V.


  • Ticker ATAI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 165,875,008
  • Market Cap $234M
  • Description
  • Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...
More about ATAI
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.